WO2003011299A3 - Treatment of ocular hypertension and glaucoma - Google Patents

Treatment of ocular hypertension and glaucoma Download PDF

Info

Publication number
WO2003011299A3
WO2003011299A3 PCT/JP2002/007699 JP0207699W WO03011299A3 WO 2003011299 A3 WO2003011299 A3 WO 2003011299A3 JP 0207699 W JP0207699 W JP 0207699W WO 03011299 A3 WO03011299 A3 WO 03011299A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
glaucoma
ocular hypertension
micrograms
keto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007699
Other languages
French (fr)
Other versions
WO2003011299A2 (en
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Priority to BR0211545-0A priority Critical patent/BR0211545A/en
Priority to KR10-2004-7001587A priority patent/KR20040023707A/en
Priority to CA002454422A priority patent/CA2454422A1/en
Priority to US10/485,370 priority patent/US20040254247A1/en
Priority to EP02751774A priority patent/EP1411950A2/en
Priority to MXPA04000980A priority patent/MXPA04000980A/en
Priority to JP2003516529A priority patent/JP2004538306A/en
Publication of WO2003011299A2 publication Critical patent/WO2003011299A2/en
Publication of WO2003011299A3 publication Critical patent/WO2003011299A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The instant invention discloses a method for treatment of ocular hypertension and glaucoma, which comprises administrating topically to the eyes of a mammalian subject in need of such treatment more than 5 micrograms and less than 50 micrograms per eye per administration of 15-keto-prostaglandin compound having a ring structure at the end of the omega chain. The treatment of the present invention causes substantially no or reduced ophthalmic irritating side effect even in such a high dose.
PCT/JP2002/007699 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma Ceased WO2003011299A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0211545-0A BR0211545A (en) 2001-07-31 2002-07-30 Method and composition for treatment of ocular hypertension and glaucoma
KR10-2004-7001587A KR20040023707A (en) 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma
CA002454422A CA2454422A1 (en) 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma
US10/485,370 US20040254247A1 (en) 2001-07-31 2002-07-30 Method and composition for treatnment of ocular hypertension and glaucoma
EP02751774A EP1411950A2 (en) 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma
MXPA04000980A MXPA04000980A (en) 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma.
JP2003516529A JP2004538306A (en) 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30858901P 2001-07-31 2001-07-31
US60/308,589 2001-07-31

Publications (2)

Publication Number Publication Date
WO2003011299A2 WO2003011299A2 (en) 2003-02-13
WO2003011299A3 true WO2003011299A3 (en) 2003-10-30

Family

ID=23194562

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2002/007699 Ceased WO2003011299A2 (en) 2001-07-31 2002-07-30 Treatment of ocular hypertension and glaucoma
PCT/US2002/024072 Ceased WO2003011178A2 (en) 2001-07-31 2002-07-31 Method for treatment of ocular hypertension and glaucoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024072 Ceased WO2003011178A2 (en) 2001-07-31 2002-07-31 Method for treatment of ocular hypertension and glaucoma

Country Status (8)

Country Link
EP (1) EP1411950A2 (en)
JP (1) JP2004538306A (en)
KR (1) KR20040023707A (en)
CN (1) CN1646134A (en)
BR (1) BR0211545A (en)
CA (1) CA2454422A1 (en)
MX (1) MXPA04000980A (en)
WO (2) WO2003011299A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215820A1 (en) * 2002-03-28 2003-10-13 Sucampo Ag Method for treating ocular hypertension and glaucoma
AR043161A1 (en) * 2003-02-14 2005-07-20 Sucampo Pharmaceuticals Inc OPHTHALM COMPOSITION TO TREAT OCULAR HYPERTENSION AND GLAUCOMA
WO2008008700A2 (en) * 2006-07-10 2008-01-17 Allergan, Inc. Substituted cyclopentane derivatives as therapeutic agents
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
JP5570807B2 (en) * 2006-07-11 2014-08-13 アラーガン インコーポレイテッド Cyclopentane derivatives as antiglaucoma drugs
RU2010103149A (en) * 2007-07-03 2011-08-10 Аллерган, Инк. (Us) THERAPEUTIC SUBSTITUTED CYCLOPENTANES TO REDUCE IN-ORGAL PRESSURE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366279A2 (en) * 1988-10-01 1990-05-02 R-Tech Ueno Ltd. Ocular hypotensive agents
WO2001068072A2 (en) * 2000-03-16 2001-09-20 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
WO2002007731A2 (en) * 2000-07-20 2002-01-31 Sucampo Ag Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366279A2 (en) * 1988-10-01 1990-05-02 R-Tech Ueno Ltd. Ocular hypotensive agents
WO2001068072A2 (en) * 2000-03-16 2001-09-20 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
WO2002007731A2 (en) * 2000-07-20 2002-01-31 Sucampo Ag Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma
US20020035149A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension and glaucoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STJERNSCHANTZ J ET AL: "MICROVASCULAR EFFECTS OF SELECTIVE PROSTAGLANDIN ANALOGUES IN THE EYE WITH SPECIAL REFERENCE TO LATANOPROST AND GLAUCOMA TREATMENT", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 19, no. 4, July 2000 (2000-07-01), pages 459 - 496, XP001126960, ISSN: 1350-9462 *

Also Published As

Publication number Publication date
MXPA04000980A (en) 2004-04-20
CN1646134A (en) 2005-07-27
WO2003011178A2 (en) 2003-02-13
JP2004538306A (en) 2004-12-24
BR0211545A (en) 2004-07-13
EP1411950A2 (en) 2004-04-28
WO2003011299A2 (en) 2003-02-13
KR20040023707A (en) 2004-03-18
CA2454422A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
CA2502437A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
WO2002096432A3 (en) Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
TWI255714B (en) Method for treating meibomian gland disease
WO2002036162A3 (en) Compositions for treatment of ocular neovascularization and neural injury
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
BR9808016A (en) Compositions and methods for reducing ocular hypertension
WO2004008990A3 (en) Multiple corneal inlays for gradual refractive correction
CA2198245A1 (en) Methods and means for drug administration
PL1654002T5 (en) Compositions for delivery of therapeutics into the eyes
EP2052720A3 (en) Use of at least one hydroxylamine compound for the treatment of eye disease
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2007038687A3 (en) Ocular administration of immunosuppressive agents
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2001030380A3 (en) Methods and compositions for treatment of keratoconus using protease inhibitors
AU5446299A (en) Medicinal compositions for treating eye diseases
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
KR20130052619A (en) Preservative free bimatoprost and timolol solutions
EP1050308A4 (en) Preventives or remedies for vision disorders
CA2171226A1 (en) Treatment of optic nerve disorder with prostanoic acid compounds
WO2003011299A3 (en) Treatment of ocular hypertension and glaucoma
WO2000074649A3 (en) Ophthalmic histamine compositions and uses thereof
AU609807B2 (en) A composition for the topical treatment of glaucoma or ocular hypertension
MXPA03010363A (en) Method for treating ocular hypertension and glaucoma.
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
Susanna Jr et al. Additive effect of latanoprost to the combination of timolol and dorzolamide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2454422

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002751774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003516529

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000980

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047001587

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002355693

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20028190947

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002751774

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10485370

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002751774

Country of ref document: EP